What is indican, what does an elevated indican level indicate, and how should it be evaluated and managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Indican: Definition, Clinical Significance, and Management

Indican (indoxyl-β-D-glucoside) is a urinary metabolite of tryptophan produced by intestinal bacteria that serves as a marker of gut dysbiosis and small intestinal bacterial overgrowth (SIBO). Elevated urinary indican levels indicate excessive bacterial fermentation of tryptophan in the small intestine, reflecting microbial imbalance rather than a primary disease state 1, 2.

What is Indican?

Indican is formed when intestinal bacteria metabolize dietary tryptophan into indole, which is then absorbed, conjugated in the liver to indoxyl sulfate, and excreted in urine as indican 3. The metabolic pathway is:

  • Dietary tryptophan → bacterial metabolism → indole → absorption → hepatic conjugation → indoxyl sulfate (uremic toxin) → urinary excretion as indican

Importantly, indoxyl sulfate is a known uremic toxin and substrate/inhibitor of organic anion transporters (OAT1, OAT3) and multidrug resistance-associated proteins (MRP4), which can interfere with drug elimination 4, 3.

Clinical Significance of Elevated Indican

Primary Indication

Elevated urinary indican concentrations indicate:

  • Intestinal dysbiosis (altered gut microbiome composition)
  • Small intestinal bacterial overgrowth (SIBO)
  • Increased intestinal permeability or malabsorption states

Disease Associations

Research demonstrates elevated indican in:

  • Parkinson's disease: Significantly higher urinary indican in both treated and de novo PD patients compared to controls, independent of constipation status 2
  • Chronic kidney disease: Indoxyl sulfate accumulates as a uremic toxin in renal failure 5, 3
  • Small intestinal dysmotility: Raised urinary indicans suggest bacterial overgrowth 6

Drug Interactions

Oral indican significantly increases systemic exposure to methotrexate (231-259% increase in AUC) by inhibiting renal OAT1, OAT3, and MRP4 transporters through its metabolite indoxyl sulfate 4. This is clinically relevant for patients taking:

  • Methotrexate
  • Other drugs eliminated via organic anion transporters
  • Medications with narrow therapeutic windows

Evaluation Approach

When to Suspect Elevated Indican

Consider testing when patients present with:

  • Chronic gastrointestinal symptoms (bloating, distension, altered bowel habits)
  • Suspected SIBO or intestinal dysmotility
  • Unexplained neurological symptoms (given PD association)
  • Drug interactions with methotrexate or similar agents
  • Recurrent small intestinal dysfunction

Diagnostic Testing

Urinary indican measurement is the primary diagnostic test:

  • Visual detection limit: 6 mg/dL using colorimetric methods 1
  • Quantitative measurement: HPLC with electrochemical detection (limits of quantitation: 5 ng/mL in serum) 5
  • Newer methods: Spectrophotometry with sodium hypochlorite pentahydrate as oxidizing agent 1

Complementary Evaluation

When elevated indican is detected, evaluate for underlying causes:

  • Stool studies: Rule out infectious causes of dysbiosis
  • Breath testing: Hydrogen/methane breath test for SIBO confirmation
  • Nutritional assessment: Vitamin B12, folate, fat-soluble vitamins (if malabsorption suspected)
  • Dietary history: Assess dairy product consumption (positively associated with elevated indican) 2
  • Medication review: Identify drugs metabolized via OAT/MRP pathways

Important Caveats

  • Ascorbic acid interferes with chromogenic detection reactions, though ascorbate oxidase can partially suppress this 1
  • Proton pump inhibitors can spuriously elevate related markers (chromogranin A), though direct interference with indican measurement is not well-documented 7, 8
  • Indican levels may fluctuate; serial measurements provide better assessment than single values

Management Strategy

Step 1: Address Underlying Dysbiosis

Primary treatment targets the gut microbiome imbalance:

  • Dietary modification:

    • Reduce fermentable carbohydrates (low FODMAP approach)
    • Limit dairy products if associated with elevated levels 2
    • Avoid excessive tryptophan-rich foods during acute phases
  • Antimicrobial therapy (if SIBO confirmed):

    • Rifaximin (standard SIBO treatment)
    • Rotate antibiotics if recurrent
    • Consider herbal antimicrobials as alternative

Step 2: Restore Gut Barrier Function

  • Probiotics: Strain-specific formulations to restore healthy microbiome
  • Prebiotics: Support beneficial bacterial growth
  • L-glutamine: For intestinal barrier repair (if increased permeability suspected)

Step 3: Manage Drug Interactions

For patients on methotrexate or similar drugs:

  • Monitor drug levels closely if indican elevation suspected
  • Adjust dosing based on therapeutic drug monitoring
  • Avoid concurrent use of indican-containing herbal preparations (Isatis indigotica, Polygonum species) 4, 3

Step 4: Treat Underlying Motility Disorders

If small intestinal dysmotility identified 6:

  • Prokinetic agents: Improve intestinal transit
  • Address constipation: Though indican elevation in PD occurs independent of constipation 2
  • Nutritional support: If malabsorption present

Step 5: Monitor Response

  • Repeat urinary indican after 4-8 weeks of treatment
  • Symptom tracking: Use validated GI symptom questionnaires
  • Nutritional markers: Reassess if deficiencies were present

Clinical Pitfalls to Avoid

  1. Do not assume constipation is the cause: Elevated indican in Parkinson's disease occurs independently of constipation 2

  2. Do not overlook drug interactions: Patients taking methotrexate with elevated indican require dose adjustment and close monitoring 4

  3. Do not rely on single measurement: Indican levels fluctuate; serial testing provides better clinical picture

  4. Do not ignore dietary factors: Dairy consumption correlates with higher indican levels 2

  5. Do not confuse with indocyanine green (ICG): These are completely different compounds; ICG is a diagnostic dye for liver function assessment 9

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.